Yes, Juvmo (tavapadon) was tested in the Phase 3 TEMPO trials (over 1,000 patients total) as monotherapy or with levodopa. Common side effects: nausea, headache, dizziness. With levodopa also dyskinesia, orthostatic hypotension, visual hallucinations. Most mild-moderate; lower rates of somnolence and impulse-control disorders than older agonists.